BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer
A Phase 1 Trial of BKM 120, a Novel Oral Selective Phosphatidylinositol-3-kinase (PI3K) Inhibitor, in Combination With Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive Metastatic Breast Cancer
Sponsor: National Cancer Institute (NCI)
Listed as NCT01339442, this PHASE1 trial focuses on Estrogen Receptor-positive Breast Cancer and Recurrent Breast Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 7 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Nov 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .